(RTTNews) - Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on developing therapies for serious rare and ultra-rare genetic diseases, on Tuesday reported a narrower loss for the third quarter of 2026, driven by higher revenues and lower research and dev
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.